GlassScriptPhysician profile
Ellen Wong Dillard
NPI 1568016244
$167,555.52
in general payments reported to CMS, 2019-2025
27 companies · $35K in 2025
The $35K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13K · 2022: $33K · 2023: $33K · 2024: $54K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $68K · Travel and Lodging: $27K · Consulting Fee: $18K · Food and Beverage: $7,892 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $67,865.00 |
| Travel and Lodging | $27,276.80 |
| Consulting Fee | $18,486.25 |
| Food and Beverage | $7,892.06 |
| Education | $194.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $153,431.38 | 2021-2025 | Tecvayli, Darzalex, Carvykti |
| Takeda Pharmaceuticals U.S.A., INC. | $9,712.98 | 2021-2023 | Iclusig |
| E.R. Squibb & Sons, L.L.C. | $496.51 | 2022-2025 | Reblozyl |
| Beigene USA, INC. | $396.40 | 2021-2025 | Brukinsa |
| Adaptive Biotechnologies Corporation | $378.69 | 2022-2023 | Clonoseq |
| Glaxosmithkline, LLC. | $355.63 | 2022-2025 | Ojjaara |
| Sanofi-Aventis U.S. LLC | $312.88 | 2023-2025 | |
| Amgen INC. | $287.28 | 2021-2022 | |
| Seagen INC. | $214.60 | 2021 | |
| Astellas Pharma US INC | $198.00 | 2022-2024 | |
| Pfizer INC. | $181.47 | 2025 | |
| Alnylam Pharmaceuticals INC. | $162.06 | 2023-2025 | Amvuttra |
| Celgene Corporation | $160.68 | 2023-2024 | Pomalyst, Reblozyl |
| Akcea Therapeutics, INC. | $150.00 | 2021 | |
| Genentech USA, INC. | $138.66 | 2023 | Venclexta |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Syndax Pharmaceuticals, INC. | $135.96 | 2025 | Revuforj |
| Astrazeneca Pharmaceuticals LP | $128.39 | 2023 | Calquence |
| Genzyme Corporation | $124.16 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $122.55 | 2022 | |
| Lilly USA, LLC | $95.17 | 2025 | |
| Novartis Pharmaceuticals Corporation | $93.97 | 2025 | |
| Tg Therapeutics, INC. | $65.59 | 2021 | |
| Jazz Pharmaceuticals INC. | $54.01 | 2025 | |
| Incyte Corporation | $50.96 | 2021 | |
| Janssen Scientific Affairs, LLC | $44.92 | 2022-2025 | Carvykti |
| Kite Pharma, INC. | $31.75 | 2025 | Yescarta |
| Alexion Pharmaceuticals, INC. | $30.87 | 2024-2025 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Dillard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.